Managing patent ductus arteriosus (PDA) remains a significant challenge for neonatologists in intensive care units. The recently published PDA RCT provides critical insights into **PDA expectant management** compared to early pharmacological intervention in extremely preterm infants. Researchers analyzed whether a less aggressive approach could reduce the high rates of morbidity associated with prematurity.

Safety and Efficacy of PDA expectant management

The multicenter trial enrolled 482 infants born between 22 and 28 weeks' gestation. Consequently, investigators compared **PDA expectant management** against active treatment with medications such as ibuprofen or acetaminophen. The results demonstrated no significant difference in the combined primary outcome of death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age.

However, the safety profile favored the conservative approach. Specifically, infants in the expectant management group had a mortality rate of 4.1%, compared to 9.6% in the active treatment group. This represents a substantial survival benefit for infants who did not receive routine drug therapy for ductal closure. Therefore, the monitoring committee stopped the trial early after identifying these differences in survival and infection-related deaths.

Furthermore, the data suggests that pharmacological closure might increase the risk of severe infections. In contrast, expectant management allows clinicians to avoid the adverse effects of NSAIDs, which can impact renal and gastrointestinal health. Moreover, this study reinforces the growing consensus that a hemodynamically significant PDA often resolves without needing immediate medical intervention.

Implications for Neonatal Care

These findings will likely change neonatal practice by establishing watchful waiting as the standard of care for most preterm infants. Clinicians should only initiate active treatment when a PDA causes clear cardiopulmonary compromise. Additionally, this shift helps minimize unnecessary drug exposure in highly vulnerable neonates. In summary, the PDA RCT highlights that a conservative strategy effectively reduces mortality without increasing the risk of chronic lung disease.

Frequently Asked Questions

What was the primary finding of the PDA RCT?

The trial concluded that expectant management is non-inferior to active pharmacological treatment regarding the incidence of death or BPD. Most notably, it showed that expectant management significantly improves overall survival rates in extremely preterm infants.

Why did the researchers stop the trial early?

The study ended early during an interim analysis for safety and futility. The data showed that active treatment doubled the risk of mortality and increased the frequency of fatal infections compared to a watchful waiting approach.

Who should receive expectant management for PDA?

Based on the trial, most infants born at 22 to 28 weeks' gestation without immediate cardiopulmonary compromise are candidates for expectant management. Clinicians should monitor these infants closely and reserve medication for symptomatic cases.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Hundscheid T et al. EBNEO Commentary: Expectant Management Versus Medication for Patent Ductus Arteriosus in Preterm Infants-The PDA RCT. Acta Paediatr. 2026 May 02. doi: 10.1111/apa.70563. PMID: 42068199.


2. Laughon MM et al. Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial. JAMA. 2026 Feb 17;335(7):588-599. doi: 10.1001/jama.2025.23330.


3. Hundscheid T, Onland W, Kooi EM, et al. Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. N Engl J Med. 2023;388(11):980-990. doi: 10.1056/NEJMoa2213203.